Pharmacokinetics and Safety of Macrocyclic Gadobutrol in Children Aged Younger Than 2 Years Including Term Newborns in Comparison to Older Populations.

@article{Kunze2016PharmacokineticsAS,
  title={Pharmacokinetics and Safety of Macrocyclic Gadobutrol in Children Aged Younger Than 2 Years Including Term Newborns in Comparison to Older Populations.},
  author={Christian Wilhelm Kunze and Hans-Joachim Mentzel and Rajesh Krishnamurthy and Robert C. Fleck and Martin Stenzel and Ravi Bhargava and Delilah M. Burrowes and Gabriele Sutter and Marcus Schultze-Mosgau and Marta Santiuste and Gabriele Hahn},
  journal={Investigative radiology},
  year={2016},
  volume={51 1},
  pages={50-7}
}
OBJECTIVES This clinical study evaluated the pharmacokinetics (PK) and safety data of macrocyclic extracellular contrast agent gadobutrol in pediatric subjects aged younger than 2 years. MATERIALS AND METHODS Pediatric subjects (term newborns to those aged younger than 2 years) with normal renal function undergoing magnetic resonance imaging with gadobutrol (0.1 mmol/kg body weight [BW]) were prospectively enrolled in this open-label, multicenter clinical trial to evaluate PK as a primary end… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 3 times. VIEW TWEETS

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

Gadobutrol: A Review in Contrast-Enhanced MRI and MRA

Clinical drug investigation • 2018
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…